. 2018 Feb 2;8:2238. doi: 10.1038/s41598-018-20502-1

Table 2.

Detection of different sub-populations of CTCs during treatment with pazopanib.

	Baseline		Post-1 ^st cycle		Progression
	Nb of +ve pts (%)	Median Nb of CTCs (range)	Nb of +ve pts (%)	Median Nb of CTCs (range)	Nb of +ve pts (%)	MedianNb of CTCs (range)
CellSearch	28/56 (50, 0%)	71 (5–11143)	7/35 (20, 0%)*	12 (5–804)^‡	18/45 (40, 0%)^a	73 (5–16806)^†
CK⁺/Ki67⁺	31/58 (53, 4%)	2 (0–19)	8/37 (21, 6%)**	0 (0–2)^‡‡	40/48 (83, 3%)^b	11 (0–79)^††
CK⁺/Ki67⁻	39/58 (67, 2%)	2 (0–57)	12/37 (32, 4%)	0 (0–19)	37/48 (77, 1%)^c	2 (0–46)^†††
CK⁺/M30⁺	9/58 (15, 5%)	0 (0–7)	13/37 (35, 1%)***	0 (0–7)^‡‡‡	5/48 (10, 4%)^d	0 (0–24)^††††
CK⁺/M30⁻	42/58 (72, 4%)	4 (0–68)	9 /37(24, 3%)****	0 (0–16)^‡‡‡‡	38/48 (79, 2%)^e	6 (0–84)^{†††††}
CK⁺/Vim⁺	43/58 (74, 1%)	8 (0–196)	11/37 (29, 7%)*****	0 (0–21)^{‡‡‡‡‡}	36/48 (75, 0%)^f	11 (0–146)^{††††††}
CK⁺/Vim⁻	33/58 (56, 9%)	1 (0–46)	9/37 (24, 3%)	0 (0–9)	28/48 (58, 3%)^g	1 (0–24)^{†††††††}

p value: Baseline vs Post 1st cycle: *0,043; **<0,001; ***0,015; ****<0,001; *****<0,001; ^‡0,043; ^‡‡<0,001; ^‡‡‡0,015; ^‡‡‡‡<0,001; ^{‡‡‡‡‡}<0,001.

p value: Post 1st vs Progression: ^a0,027; ^b<0,001; ^c0,004; ^d0,001; ^e<0,001; ^f<0,001; ^g0,017; ^†0,027; ^††0,001; ^†††0,04, ^††††0,001; ^{†††††}<0,001, ^{††††††}<0,001; ^{†††††††}0,017.